Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Achaogen Raises $56M In Series C Round To Advance Next-Generation Antibiotic Programs

This article was originally published in The Pink Sheet Daily

Executive Summary

Achaogen turns to VC backers to advance its lead compound into Phase II trials for complicated urinary tract infections.

You may also be interested in...



Optimer’s Dificid Could Pave A Path To Higher Prices For Antibiotics

The drug developer appears to be making the case for premium pricing by differentiating fidaxomicin for its ability to sustain clinical response and cut costs associated with recurrence.

Tetraphase Raises $45 Mil. In Series C Round, Enough To Finish Phase II For Next-Gen Antibiotic

Tetraphase is keeping its exit options open, hoping for either an initial public offering, a licensing deal or an acquisition down the road.

Tetraphase Raises $45 Mil. In Series C Round, Enough To Finish Phase II For Next-Gen Antibiotic

Tetraphase is keeping its exit options open, hoping for either an initial public offering, a licensing deal or an acquisition down the road.

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel